HOME >> BIOLOGY >> NEWS
Vion's TAPET® administered to first patients in Phase I human intratumoral safety trial at the Cleveland Clinic Foundation

alization of cancer treatment technologies. Vion's product portfolio consists of TAPET, a drug delivery platform, and three cancer therapeutics (Promycin, Triapine and Sulfonyl Hydrazine Prodrugs). TAPET has been shown in preclinical models to effectively deliver anticancer agents while having a minimal toxic effect on healthy normal tissues. TAPET uses genetically altered strains of Salmonella as a bacterial vector, or vehicle, for delivering cancer fighting drugs preferentially to solid tumors. Promycin, which attacks oxygen depleted cancer cells, is currently being evaluated with radiation in a multicenter Phase III clinical trial for the treatment of head and neck cancer. Triapine, which is designed to prevent the replication of tumor cells by blocking a critical step in the synthesis of DNA, is currently being evaluated for its safety in a Phase I clinical trial. Sulfonyl Hydrazine Prodrugs, compounds that are designed to be converted to unique potent, alkylating agents, are currently being evaluated in preclinical studies.


'"/>

Contact: Sue Yeoh
syeoh@cpronline.com
201-641-2408 x43
Vion Pharmaceuticals, Inc.
8-Dec-1999


Page: 1 2

Related biology news :

1. Vions TAPET Organisms Demonstrate Reduced Virulence, Increased Safety While Retaining Ability To Specifically Target Tumors
2. New study indicates arsenic could be suitable as first-line treatment in type of leukaemia
3. Newly identified master gene key in babys first breath
4. The book opens on the first tree genome
5. DuPont developing new protective suits for military, first responders
6. Joslin Diabetes Center adds first affiliate in California at Irvine Medical Center
7. Maine-based biophysics institute gets funding for first US-based 4Pi nanoscale microscope
8. Veterinarians discover first known case of canine distemper in a wild tiger
9. Study reveals first genetic step necessary for prostate cancer growth
10. The first engineering of cell surfaces in living animals
11. Infant rats eagerly accept high concentrations of alcohol upon first exposure

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/10/2019)... ... October 09, 2019 , ... Calcium & Bone Health Institute ... in Vancouver, Canada on September 23-24 for two days. The purpose of symposium ... healthy bone and to prevent calcium-related diseases. The theme of this year was ...
(Date:10/8/2019)... ... October 08, 2019 , ... ... National Research Council of Canada (NRC) to create the Laboratory of Industrial ... and in manufacturing, LIFT will offer a competitive capacity to accelerate the ...
(Date:10/8/2019)... ... October 07, 2019 , ... ... of imaging modalities such as optical projection tomography, optical coherence tomography, echocardiogram, light ... to generate these data sets inhouse, a lot of research groups struggle with ...
Breaking Biology News(10 mins):
(Date:10/3/2019)... ... 2019 , ... Cheyenne is a beautiful and strong Quarter Horse and a ... Rebel’s Run , which offers riding lessons and trail riding in Afton, Virginia. ... Mimi describes her as her “go to horse.” Thus, you can imagine ...
(Date:10/3/2019)... BOSTON (PRWEB) , ... October 03, 2019 , ... Yesterday, ... 2-3, Asymmetrex founder and director, James L. Sherley, M.D., Ph.D., discussed important ... To an attendee audience including both developers and suppliers of clinical trials, in ...
(Date:9/24/2019)... ... September 24, 2019 , ... Personalized ... training and site qualification for clinical trial sites and physician investigators. The ... potential clinical trial participants. , Clinical trial sites are currently located in San ...
(Date:9/17/2019)... , ... September 17, 2019 , ... Tucker, a Labrador ... only four months old, Tucker was limping and lame on his right hip and ... dysplasia and it was called “the worst case the vet had seen.” He was ...
Breaking Biology Technology:
Cached News: